Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults
Authors Thomas BM, Farquhar-Smith P
Received 20 June 2013
Accepted for publication 20 July 2013
Published 25 November 2013 Volume 2013:9 Pages 469—475
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Ben M Thomas,1 Paul Farquhar-Smith2
1Chelsea Westminster Hospital, London, UK; 2Department of Anaesthetics, The Royal Marsden NHS Foundation Trust, London, UK
Abstract: The development of biomedical technology is allowing refinement of drug therapies in order to improve medication profiles and benefit patients. Gabapentin (Gp) is a medication licensed globally for various indications, including postherpetic neuralgia. It has a pharmacokinetic profile which has been suggested may limit its clinical effects and reduce medication compliance. In 2012, the US Food and Drug Administration licensed a novel preparation which aims to circumvent these limitations. Gp enacarbil is a prodrug of Gp, which is additionally prepared in an extended release preparation. The resulting compound has an improved absorption profile and a reduced dosing frequency in comparison to immediate release Gp. An absence of comparative data, however, limits the direct evaluation of the medication to both immediate release and other extended release preparations available on the market. Additionally, no data are currently available addressing efficacy, tolerability, or side effects with other first line treatments of postherpetic neuralgia. Additional experimental data should be sought to clarify the position of Gp enacarbil, both within postherpetic neuralgia treatment protocols and in relation to the increasing numbers of gabapentinoids available.
Keywords: postherpetic neuralgia, garbapentin enacarbil, herpes zoster
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.